Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Tirzepatide/B12 From $45/12mg Dual GIP/GLP-1 receptor agonist for enhanced metabolic support with B12
AOD-9604 Adolescent (12 to 17) Dosing: What Clinicians and Parents Need to Know At a glance Regulatory status / No FDA approval for any indication or age group Typical research dose in adults / 250 to 500 mcg subcutaneous once daily (not validated in adolescents) Adolescent trial evidence / Zero published RCTs in the 12, 17 age group Key safety concern / Potential interference with growth-plate biology and pubertal GH axis Compounding status / Available only through 503A compounding pharmacies under prescriber order Primary preclinical evidence / Heffernan et al
[2] If you experience concerning symptoms after an injection, seek medical advice and consider reporting suspected side effects through the MHRA Yellow Card scheme
Consult your doctor prior to starting this medicine
US$ 29.12
US$ 22.86
US$ 28.77
US$ 23.81
US$ 20.04
